NCT07167524View on ClinicalTrials.gov

Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam

Not yet recruitingOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

April 1, 2028

Conditions
SepsisSevere Bacterial Infections
Interventions
BIOLOGICAL

Dosage concentration of piperacillin and tazobactam

The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.

Trial Locations (1)

76031

University Rouen Hospital, Rouen

All Listed Sponsors
lead

University Hospital, Rouen

OTHER

NCT07167524 - Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam | Biotech Hunter | Biotech Hunter